Cordier D, Forrer F, Bruchertseifer F, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335–44.
Deal KA, Davis IA, Mirzandeh S, Kennel SJ, Brechbiel MW. Improved In Vivo Stability of Actinium-225 Macrocyclic Complexes. J Med Chem. 1999;42:2988–92.
Hallqvist A, Bergmark K, Bäck T, et al. Intraperitoneal α-emitting radioimmunotherapy with 211At in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations. J Nucl Med. 2019;60:1073–9.
Ho TK. Random decision forests. In: Paper presented at: 3rd international conference on document analysis and recognition; 14–16 Aug, 1995; Montreal, CA.
Juric JG, Levy MY, Park JH, et al. Phase I trial of α-particle therapy with Actinium-225 (225Ac)-Lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML). Blood. 2016;128:4050.
Kelly JM, Amor-Coarasa A, Nikolopoulou A, et al. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3+. Nucl Med Biol. 2017;55:38–46.
Kelly JM, Amor-Coarasa A, Ponnala S, et al. A single dose of 225Ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model. J Nucl Med. 2019a;60:66.
Kelly JM, Amor-Coarasa A, Ponnala S, et al. Albumin-binding PSMA ligands: implications for expanding the therapeutic window. J Nucl Med. 2019b;60:656–63.
Khreish F, Ebert N, Ries M, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8.
Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19.
Kratochwil C, Bruchertseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC—an empiric dose finding for alpha emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56:1232.
Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.
Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.
Krolicki L, Bruchertseifer F, Morgenstern A, et al. Safety and therapeutic efficacy of 225Ac-DOTA-substance p for therapy of brain tumors. J Med Imaging Radiat Sci. 2019;50:S22.
Kruijff RMd, Wolterbeek HT, Denkova AG. A critical reviw of alpha radionuclide therapy—how to deal with recoiling daughters? Pharmaceuticals. 2015;8:321–36.
Kruijff RMd, Raavé R, Kip A, et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9:11671.
Li L, Rousseau J, Jaraquemada-Peláez MdG, et al. 225Ac-H4py4pa for targeted alpha therapy. Bioconjug Chem. 2020. https://doi.org/10.1021/acs.bioconjchem.1020c00171.
Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22.
McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841–7.
Meredith RF, Torgue JJ, Rozgaja TA, et al. Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41:716–21.
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200–8.
Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with α-emitting Radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.
Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27:868–74.
Perron R, Gendron D, Causey PW. Construction of a thorium/actinium generator at the Canadian Nuclear Laboratories. Appl Radiat Isot. 2020;164:109262.
Poty S, Membreno R, Glaser JM, et al. The inverse electron-demand Diels–Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates. Chem Commun (Camb). 2018;54:2599–602.
Ramogida CF, Robertson AKH, Jermilova U, et al. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac. EJNMMI Radiopharm Chem. 2019;4:21.
Robertson AKH, Ramogida CF, Rodríguez-Rodríguez C, et al. Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies. Phys Med Biol. 2017;62:4406–20.
Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11:156–72.
Rosenblat TL, McDevitt MR, Mulford DA, et al. Sequential cytarabine and α-particle immunotherapy with Bismuth-213–Lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16:5303–11.
Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.
Scheinberg DA, McDevit MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011;4:306–20.
Shukurov R, Veliyev M, Dadashov Z, Isayev J, Novruzov F. Labeling process and quality control results of 225Ac-PSMA-617 for targeted alpha particle therapy for metastatic prostate cancer. J Nucl Med. 2019;60:1611.
Song HA, Kang CS, Baidoo KE, et al. An efficient bifunctional decadentate ligand 3p-C-DEPA for targeted alpha radioimmunotherapy applications. Bioconjug Chem. 2011;22:1128–35.
Tagawa ST, Vallabhajosula S, Jhanwar Y, et al. Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36:TSP399.
Thiele NH, Brown V, Kelly JM, et al. An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy. Angew Chem Int Ed. 2017;56:14712–7.
Thiele NA, Wilson JJ. Actinium-225 for targeted α therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. 2018;33:336–48.
Tichacek CJ, Budzevich MM, Wadas TJ, Morse DL, Moros EG. A Monte Carlo method for determining the reesponse relationship between two commonly used detectors to indirectly measure alpha particle radiation activity. Molecules. 2019;24:3397.
Yang H, Zhang C, Yuan Z, et al. Synthesis and evaluation of a macrocyclic Actinium-225 chelator, quality control and in vivo evaluation of 225Ac-crown-αMSH peptide. Chem Eur J. 2020;26:11435–40.
Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30–8.